Caligan Partners as of Sept. 30, 2023
Portfolio Holdings for Caligan Partners
Caligan Partners holds 13 positions in its portfolio as reported in the September 2023 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Liquidia Corp Com New (LQDA) | 26.9 | $59M | 9.2M | 6.34 | |
| Alimera Sciences Com New | 24.0 | $52M | 17M | 3.10 | |
| Intercept Pharmaceuticals Put Put Option | 10.2 | $22M | 1.2M | 18.54 | |
| D Fluidigm Corp Del (LAB) | 10.2 | $22M | 7.6M | 2.90 | |
| Anika Therapeutics (ANIK) | 9.3 | $20M | 1.1M | 18.63 | |
| Exelixis (EXEL) | 9.1 | $20M | 911k | 21.85 | |
| Evolus (EOLS) | 7.1 | $15M | 1.7M | 9.14 | |
| Verona Pharma Sponsored Ads (VRNA) | 1.4 | $3.0M | 183k | 16.30 | |
| Adma Biologics (ADMA) | 1.0 | $2.1M | 598k | 3.58 | |
| Verrica Pharmaceuticals (VRCA) | 0.5 | $1.0M | 260k | 3.89 | |
| Recro Pharma | 0.4 | $794k | 1.7M | 0.47 | |
| Y Mabs Therapeutics (YMAB) | 0.1 | $127k | 23k | 5.45 | |
| Agios Pharmaceuticals (AGIO) | 0.1 | $120k | 4.8k | 24.75 |
